Kyverna Therapeutics, Inc. KYTX Payments Of Stock Issuance Costs
Payments Of Stock Issuance Costs at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.
The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s payments of stock issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s payments of stock issuance costs?
- Kyverna Therapeutics, Inc. (KYTX) reported payments of stock issuance costs of $69K in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s payments of stock issuance costs changed year-over-year?
- Kyverna Therapeutics, Inc.'s payments of stock issuance costs decreased by 9.2% year-over-year, from $76K to $69K.
- What does payments of stock issuance costs mean?
- This captures the direct cash costs incurred in connection with the issuance of equity securities, such as legal, accounting, and registration fees. These costs are typically deducted from the gross proceeds of the offering. Monitoring these expenses helps investors understand the efficiency of the company's capital-raising activities.